HUP0003885A2 - Formulation for treating congestive heart failure - Google Patents

Formulation for treating congestive heart failure

Info

Publication number
HUP0003885A2
HUP0003885A2 HU0003885A HUP0003885A HUP0003885A2 HU P0003885 A2 HUP0003885 A2 HU P0003885A2 HU 0003885 A HU0003885 A HU 0003885A HU P0003885 A HUP0003885 A HU P0003885A HU P0003885 A2 HUP0003885 A2 HU P0003885A2
Authority
HU
Hungary
Prior art keywords
formulation
heart failure
congestive heart
treating congestive
active ingredient
Prior art date
Application number
HU0003885A
Other languages
Hungarian (hu)
Inventor
John L. McNay
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0003885A2 publication Critical patent/HUP0003885A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya orális vagy beültetendő, a hatóanyagot nem azonnalfelszbadító gyógyszerkészítmény, mely a monoxinidinnek vagygyógyászati szempontból alkalmazható sójának hatásos mennyiségéttartalmazza egy vagy több vivőanyag, hígító- vagy köztes anyagkíséretében, melyek biztosítják, hogy a hatóanyag nem azonnal szabadulfel a készítményből. ÓThe subject of the invention is an oral or implantable pharmaceutical preparation that does not immediately release the active ingredient, which contains an effective amount of monoxinidine or its salt that can be used from a medical point of view, accompanied by one or more carriers, diluents or intermediates, which ensure that the active ingredient is not immediately released from the preparation. HE

HU0003885A 1996-06-06 1997-06-05 Formulation for treating congestive heart failure HUP0003885A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (1)

Publication Number Publication Date
HUP0003885A2 true HUP0003885A2 (en) 2001-04-28

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003885A HUP0003885A2 (en) 1996-06-06 1997-06-05 Formulation for treating congestive heart failure

Country Status (17)

Country Link
EP (1) EP0914128A1 (en)
JP (1) JP2000511906A (en)
KR (1) KR20000016406A (en)
CN (1) CN1226166A (en)
AU (1) AU3233197A (en)
BR (1) BR9709546A (en)
CA (1) CA2256720A1 (en)
CZ (1) CZ397698A3 (en)
EA (1) EA199900006A1 (en)
HU (1) HUP0003885A2 (en)
IL (1) IL126966A0 (en)
NO (1) NO985695L (en)
PL (1) PL330637A1 (en)
TR (1) TR199802496T2 (en)
WO (1) WO1997046241A1 (en)
YU (1) YU55998A (en)
ZA (1) ZA974978B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (en) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
SK10082001A3 (en) * 1999-02-01 2002-04-04 Solvay Pharmaceuticals Gmbh Use of moxonidine for postmyocardial infarction treatment
DE602006018139D1 (en) * 2006-08-31 2010-12-23 Chemagis Ltd Use of the monoxidine salts to purify monoxide
KR100812287B1 (en) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 Shade for a traffic signal lamp having reflective layer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (en) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermal drug
DE3729299A1 (en) * 1987-09-02 1989-03-23 Beiersdorf Ag TRANSDERMAL THERAPEUTIC SYSTEM
DE3904795C2 (en) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmaceutical preparation and its use
DE4325491A1 (en) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism
DE4423177A1 (en) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglycemic drugs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
EP0914128A1 (en) 1999-05-12
KR20000016406A (en) 2000-03-25
JP2000511906A (en) 2000-09-12
NO985695D0 (en) 1998-12-04
AU3233197A (en) 1998-01-05
IL126966A0 (en) 1999-09-22
ZA974978B (en) 1998-12-07
YU55998A (en) 1999-11-22
NO985695L (en) 1999-02-04
BR9709546A (en) 1999-08-10
CA2256720A1 (en) 1997-12-11
WO1997046241A1 (en) 1997-12-11
TR199802496T2 (en) 1999-02-22
EA199900006A1 (en) 1999-06-24
CZ397698A3 (en) 1999-05-12
CN1226166A (en) 1999-08-18
PL330637A1 (en) 1999-05-24

Similar Documents

Publication Publication Date Title
NO20101190L (en) Use of buprenorphine in the manufacture of a medicament
IS2148B (en) (Methylsulfonyl) phenyl-2- (5H) -furanone inhibited by COX-2
ATE220896T1 (en) CONTROLLED RELEASE HYDROGEL FORMULATION
AU3990797A (en) Sustained release formulation
DE60100595D1 (en) Improved transdermal therapeutic system for the treatment of Parkinson's disease
BR9912066A (en) Use of an active ingredient; restenosis treatment method; and; pharmaceutical composition
CY1106763T1 (en) PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES
ATE201597T1 (en) ADMINISTRATION OF RILUZOLE FOR THE TREATMENT OF NEURO-AIDS
NO951498D0 (en) Pharmaceutical preparation for the treatment of osteoporosis
UA35567C2 (en) Pharmaceutical preparation for treating patients with coagulation impairment, method for treatment, method for pharmaceutical manufacturing
DK0499923T3 (en) Dental Adhesive
DK0998287T3 (en) Use of levobupivacaine
HUP0104647A2 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
NO20000446D0 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
HUP0003885A2 (en) Formulation for treating congestive heart failure
DE59608150D1 (en) TRANSDERMAL THERAPEUTIC SYSTEM (TTS) FOR THE ADMINISTRATION OF TESTOSTERONE
GB9907571D0 (en) Compounds
MXPA02003484A (en) Synergistic combinations of an nk1.
TR199700963T1 (en) Derivative of aminotetral for the treatment of cardiovascular diseases.
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
BR0015781A (en) Pharmaceutical composition for treatment of diseases associated with decreased bone mass
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
HUP0000110A2 (en) Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain
WO2002089848A3 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
SE9602262D0 (en) New use of cystine derivatives